Related Experiment Video

Updated: Oct 19, 2026

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

Synergistic antitumor effects of HER2/neu antisense oligodeoxynucleotides and conventional chemotherapeutic agents

H Roh1, C B Hirose, C B Boswell

  • 1Department of Surgery, Washington University School of Medicine, St Louis, MO 63110, USA.

Surgery
|August 24, 1999
PubMed
Abstract

Insights

Antisense therapy targeting the HER2/neu oncogene can enhance chemotherapy effectiveness against HER2/neu overexpressing tumors. This combination therapy shows synergistic antitumor effects in vitro and in vivo.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • HER2/neu oncogene overexpression is common in human tumors.
  • HER2/neu overexpressing tumors may exhibit intrinsic resistance to chemotherapy.
  • Investigating strategies to overcome chemoresistance in HER2/neu positive cancers is crucial.

Purpose of the Study:

  • To evaluate if antisense-mediated downregulation of HER2/neu expression can enhance chemotherapy efficacy.
  • To assess the combined effects of HER2/neu antisense oligodeoxynucleotides (ODNs) and chemotherapeutic agents.
  • To determine the impact on tumor cell proliferation and apoptosis.

Main Methods:

  • In vitro studies assessed the effects of HER2/neu antisense ODNs combined with various chemotherapeutic agents on tumor cell growth and apoptosis.
  • In vivo experiments utilized human tumor xenografts in nude mice to evaluate the combination of HER2/neu antisense ODNs and doxorubicin hydrochloride.
  • Tumor growth inhibition and synergistic activation of apoptosis were key outcome measures.

Main Results:

  • Combination therapy involving HER2/neu antisense ODNs and chemotherapeutic agents demonstrated additive or synergistic inhibition of tumor cell proliferation.
  • Synergistic activation of apoptosis was observed with the combination therapy.
  • In vivo studies showed synergistic antitumor effects when HER2/neu antisense ODNs were combined with doxorubicin hydrochloride.

Conclusions:

  • Downregulating HER2/neu expression can sensitize HER2/neu overexpressing human cancers to chemotherapy.
  • Antisense ODNs targeting HER2/neu represent a potential therapeutic strategy for enhancing cancer treatment outcomes.
  • This approach may improve the efficacy of conventional chemotherapy in specific cancer types.

More Related Videos

Analysis of Targeted Viral Protein Nanoparticles Delivered to HER2+ Tumors11:52

Analysis of Targeted Viral Protein Nanoparticles Delivered to HER2+ Tumors

Published on: June 18, 2013

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

Related Concept Videos

Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...